Clinical Trial

Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 11, 2022 (before its estimated December 2022 completion). Its status may not reflect the trial's current state.
Summary
Primary Objective: * To determine whether changes in uptake of \[18F\]DCFPyL PET/CT scans at baseline and after 6 weeks of treatment for metastatic castrate resistant prostate cancer, correlates with radiographic progression free survival (rPFS) as defined by Prostate Cancer Working Group 3 (PCWG3) criteria. Secondary Objectives: * To determine whether changes in uptake of \[18F\]DCFPyL PET/CT scans correlate with overall survival (OS) * To determine whether baseline SUVmax correlate with rPFS * To compare number of lesions detected with standard imaging at baseline and at the time of progression
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2018-06-29; most recent amendment 2024-03-04.
Status change: Active, Not Recruiting → Completed 2024-03-04
Status change: Recruiting → Active, Not Recruiting 2022-05-06
Status change: Not Yet Recruiting → Recruiting 2019-03-27
Trial Details
NCT Number NCT03585114
Lead Sponsor Columbia University
Conditions Metastatic Prostate Cancer
Enrollment 11 participants
Start Date 2018-12-11
Primary Completion 2022-12 (estimated)
Study Completion 2022-12 (estimated)
Updated on ClinicalTrials.gov 2022-05-11